NCT05388370 2026-03-12
PASS of Paediatric Patients Initiating Selumetinib
AstraZeneca
Active not recruiting
Clinical Trials
12 trialsNCT07221331 2026-02-24
PRECIOUS Egypt
AstraZeneca
Recruiting
NCT05101148 2026-02-23
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
AstraZeneca
Phase 1 Active not recruiting
NCT03975829 2026-02-13
Pediatric Long-Term Follow-up and Rollover Study
Novartis
Phase 4 Active not recruiting
NCT04590235 2026-01-30
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
AstraZeneca
Phase 1 Active not recruiting
NCT04924608 2026-01-12
KOMET
AstraZeneca
Phase 3 Active not recruiting
NCT05309668 2025-12-18
SPRINKLE
AstraZeneca
Phase 1/2 Active not recruiting
NCT06961565 2025-12-04
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
Pasithea Therapeutics Corp.
Phase 1 Recruiting
NCT06541847 2025-11-21
INSPIRE-NF1
Healx Limited
Phase 2 Recruiting
NCT03962543 2025-08-07
ReNeu
SpringWorks Therapeutics, Inc.
Phase 2 Active not recruiting
NCT07024394 2025-06-17
Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1/2 Not yet recruiting
NCT05683678 2025-04-04
US Selumetinib Registry
Alexion Pharmaceuticals, Inc.
Terminated